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Abstract. Bombesin receptor subtype-3 (BRS-3) is an orphan 
G-protein-coupled receptor (GPCR) member of the bombesin 
receptor family. Several studies have suggested an association 
between obesity, alterations in glucose metabolism, diabetes 
and the BRS-3 receptor. In this study, we focused on patients 
simultaneously diagnosed with obesity and type 2 diabetes (OB/
T2D). The analysis of BRS-3 expression in the skeletal muscle 
of these patients revealed a marked decrease in the expression of 
BRS-3 at the mRNA (23.6±1.3-fold downregulation, p<0.0001) 
and protein level (49±7% decrease, p<0.05) compared to the 
normal patients (no obesity and diabetes). Moreover, in cultured 
primary myocytes from patients with OB/T2D, the synthetic 
BRS-3 agonist, [D-Try6,β-Ala11,Phe13,Nle14]bombesin6-14, signifi-
cantly increased the phosphorylation levels of mitogen-activated 
protein kinase (MAPK), p90RSK1, protein kinase B (PKB) 
and p70s6K. Specifically, the ligand at 10-11 M induced the 
maximal phosphorylation of MAPKs (p42, 159±15% of the 
control; p44, 166±11% of the control; p<0.0001) and p90RSK1 
(148±2% of the control, p<0.0001). The basal phosphorylation 
levels of all kinases were reduced (p<0.05) in the patients with 
OB/T2D compared to the normal patients. Furthermore, the 
BRS-3 agonist stimulated glucose transport, which was already 
detected at 10-12 M (133±9% of the control), reached maximal 
levels at 10-11 M (160±9%, p<0.0001) and was maintained at 
up to 10-8 M (overall mean, 153±7%; p<0.007). This effect was 
less promiment than that attained with 10-8 M insulin (202±9%, 
p=0.009). The effect of the agonist on glycogen synthase a 
activity achieved the maximum effect at 10-11 M (165±16% of 
the control; p<0.0001), which did not differ from that observed 
with higher concentrations of the agonist. These results suggest 
that muscle cells isolated from patients with OB/T2D have 
extremely high sensitivity to the synthetic ligand, and the effects 
are particularly observed on MAPK and p90RSK1 phosphory-
lation, as well as glucose uptake. Moreover, our data indicate 
that BRS-3 may prove to be useful as a potential therapeutic 
target for the treatment of patients with OB/T2D.
Introduction
Bombesin receptor subtype-3 (BRS-3) is a G-protein-coupled 
receptor (GPCR), a member of the bombesin receptor family, 
which is present in both the central nervous system and the 
peripheral tissues, including muscle (1-5). It is frequently over-
expressed in various types of tumor tissue (1,6,7), thus playing 
an important role in lung tumor invasiveness (8).
Moreover, the BRS-3 receptor seems to be associated with 
glucose homeostasis. Several studies on adipose tissue and 
animal models (2,9-12) have suggested an association between 
obesity, alterations in glucose metabolism and the BRS-3 
receptor. Of note, in BRS-3 knockout (KO) mice, this receptor 
has been implicated in insulin release (11), as well as in the 
development of metabolic defects and obesity (2). Additionally, 
a recent study reported that the BRS-3 receptor in humans is 
involved in the regulation of glucose-stimulated insulin secre-
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tion (13). Moreover, human skeletal muscle expresses functional 
BRS-3, and lower than normal BRS-3 mRNA/protein levels 
have been detected in patients with obesity and type 2 diabetes 
(OB/T2D) (5). All the aforementioned data suggest an associa-
tion between BRS-3 and human metabolic alterations (5).
BRS-3 has a low affinity for all naturally occurring 
bombesin-related peptides, as well as most synthetic bombesin-
family member analogues (8,14). BRS-3 is an orphan receptor, 
whose natural ligand has not yet been described, although 
numerous studies on the synthetic agonists of BRS-3 have 
been carried out (9,13,15,16). Specifically, studies on Bag-1 and 
MK-5046 have demonstrated that these compounds stimulate 
an increase in glucose-mediated insulin secretion in insulinoma 
cell lines (INS-1 832/3 and MIN6), and in vivo, they also exert 
several anti-obesity effects (9,13,15,16). In BALB/3T3 cells 
overexpressing the human BRS-3 receptor, MK-5046 and the 
synthetic bombesin analogue, [D-Tyr6,β-Ala11,Phe13,Nle14]
bombesin6-14, have shown high affinity for the receptor, and both 
compounds stimulate kinases involed in insulin signaling, such 
as p125FAK, phosphorylated AKT (pAKT) and mitogen-activated 
protein kinase (MAPK) phosphorylation (17). Moreover, in 
cultured primary myocytes from normal subjects, obese patients, 
or patients with T2D, where BRS-3 is natively expressed, 
the insulin-mimetic effects of [D-Tyr6,β-Ala11,Phe13,Nle14]
bombesin6-14 have been reported, which involve an increase in 
kinase phosphorylation [MAPKs, p90RSK1, protein kinase B 
(PKB) and p70s6K], thus improving glucose metabolism, with 
cells from obese patients and patients with T2D being more 
sensitive to the ligand than cells from normal subjects (18).
BRS-3 seems to play a role in glucose metabolism, not only in 
normal subjects, but also in obese patients and patients with T2D. 
Furthermore, its ligand is capable of improving glucose parame-
ters through common insulin signaling pathways. In the current 
study, we aimed to assess the following: i) the status of BRS-3 in 
skeletal muscle tissue from patients simultaneously diagnosed 
with OB/T2D, ii) the effects of [D-Tyr6-β-Ala11,Phe13,Nle14]
bombesin6-14 on glucose-related processes in primary cultured 
myocytes, and iii) the role of BRS-3 and its synthetic agonist, 
as well as the potential therapeutic application of the synthetic 
agonist for patients with OB/T2D.
Materials and methods
Reagents. [D-Tyr6-β-Ala11,Phe13,Nle14]bombesin6-14 was 
obtained from Anaspec (Fremont, CA, USA); pork-insulin was 
from Novo BioLabs (Bagsvaerd, Denmark); the RNeasy Fibrous 
Tissue kit was purchased from Qiagen (Valencia, CA, USA); 
HAM'S-F-10, M-199 and Dulbecco's modified Eagle's medium 
(DMEM) were obtained from (Biochrom KG, Berlin, Germany); 
ethylenediaminetetraacetic acid (EDTA), rat-collagen, α-tubulin 
antibody (T 5168) and primers were from Sigma Chemical Co. 
(St. Louis, MO, USA); UDP-14C-glucose was from American 
Radiolabeled Chemicals, Inc. [(ARC), St. Louis, MO, USA]; 
cytochalasin-B and 2-deoxy-D-[1,2-3H(N)]glucose were from 
Hartmann-Analytic (Braunschweig, Germany); Ultima Gold 
scintillation liquid was obtained from Packard, (Gröninger, 
The Netherlands); anti-BRS-3 (PA5-26484) central region of 
human BRS-3 was from Pierce Biotechnology (Rockford, IL, 
USA); horseradish peroxidase-conjugated donkey anti-rabbit 
immunoglobulin (NA934), rainbow markers, the ECL western 
blotting kit and Hyperfilm-ECL were obtained from Amersham 
Biosciencies (Buckinghamshire, UK); the rabbit anti-total/
anti-phosphorylated-form of p44/42MAPK (#9102/#9101), 
p70s6K (#9202/#9204) and PKB (#9272/#9271S) were from 
Cell Signaling Technology - New England Biolabs (Beverly, 
MA, USA); the phosporylated form of p90RSK1 (ref. 01-418) 
was from Millipore (Temecula, CA, USA), the high-capacity 
cDNA reverse transcription kit was from Applied Biosystems 
(Cheshire, UK) and Premix Ex Taq™ was from Takara Clontech 
(Mountain View, CA, USA). All other commonly used chemi-
cals were from Sigma or Merck (Merck Pharma Quimica, S.A., 
Barcelona, Spain).
Biological materials. Human skeletal muscle samples were 
obtained after informed consent from normal subjects without 
any alterations in glucose metabolism, as indicated by normal 
levels of glucose and glycated hemoglobin (hemoglobin A1c; 
HbA1c), as well as from patients with OB/T2D (Table I) under-
going surgery for well-established clinical conditions [surgery 
in normal subjects was for conditions such as subtotal thyroid-
ectomy) and bariatric surgery for patients with OB/T2D]. The 
patients underwent surgery for purposes not related to this 
study. This study was approved by the Ethics Committee of the 
IIS-Jiménez Díaz Foundation, Madrid, Spain, in accordance 
with the ethical principles stated in the Declaration of Helsinki. 
The samples were cleaned with HAM's F-10, dissected from 
the connecting tissue and divided into sections of 120 and 
400 mg. The first set was stored at -80˚C for the extraction of 
total RNA. However, in the 400 mg sections, the isolation of 
myoblasts and posterior culture for growth and differentiation 
were performed inmmediately following isolation as previ-
ously described (19). In the OB/T2D group, all patients were 
Table I. Metabolic characteristics of patients with obese/type 2 
diabetes (OB/T2D) and normal subjects included in the study.
 Patients with Normal
 OB/T2D subjects
Female/male 3/7 19/4
Age (years) 49±3 50±3
BMI (kg/m2) 51±3a 24±1
Glucose (mg/dl) 112±6a 96±2
HbA1c 6.4±0.2 4.8±0.3
Cholesterol (mg/dl) 184±9 185±9
HDL (mg/dl) 48±4 56±3
LDL (mg/dl) 110±9 116±6
Tryglycerides (mg/dl) 147±18a 98±9
Years from diagnosis  4.3±1.0 -
of type 2 diabetes
Treatment Metformin
 (1,700-2,550 mg) -
Values are the means ± SEM. Normal subjects, n=23; patients with 
OB/T2D patients, n=10. ap<0.001 vs. normal subjects. BMI, basal 
metabolic rate; HbA1c, hemoglobin A1c; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  35:  925-931,  2015 927
prescribed with oral antidiabetic drugs (Table I). The normal 
subjects did not receive glucose-related drugs. In all cases, the 
isolated myoblasts were grown for 6 weeks in 5.5 mM glucose 
and insulin-free medium. No differences in the growth rate or 
cell morphology were observed (data not shown).
Isolation of total RNA and reverse transcrtipion-quantitative 
(real-time) PCR (RT-qPCR). Total RNA was isolated from the 
sections of human skeletal muscle tissue using the RNeasy 
Fibrous Tissue kit, according to the manufacturer's instructions. 
For RT-qPCR, cDNA was synthesized from 3 µg (BRS-3) of 
total RNA using the High Capacity cDNA Reverse Transcription 
kit. The samples from the skeletal muscle sections were 
subjected to quantitative amplification using the primer sets for 
human BRS-3 (5'-GGCAGTTGTGAAGCCACTTGA-3' and 
5'-AGACGCAGCCAGCTTTTACAC-3'), Premix Ex Taq™ 
and the StepOne Real-Time PCR system (Applied Biosystems). 
The conditions for amplification and detection (2 min at 95˚C; 
50 cycles of 15 sec at 95˚C; 30 sec at 60˚C) were optimized, and 
gene expression was normalized to that of the housekeeping 
18S gene. The mRNA copy numbers were calculated for each 
sample using the cycle threshold (Ct) value, and the results were 
expressed as n-fold mRNA values as previously reported by 
Livak and Schmittgen (20).
Immunoblotting. Tissue samples (120 mg) were homogenized 
at 4˚C in 1,25% Triton X-100 containing 250 mM sucrose, 
20 mM Tris/HCl, 2·5 mM MgCl2, 50 mM β-mercaptoethanol, 
1,2 mM EGTA, 1 mM Na3VO4, 5 mM Na4P2O7, 50 mM NaF, 
2 µM leupeptin, 2 µM pepstatin, pH 7.4 and 2 mM phenyl-
methylsulfonyl fluoride, then maintained at 4˚C for 30 min, 
and finally centrifuged at 15,000 x g. The supernatant (tissue 
lysate), containing cytosolic and solubilized membranes, was 
kept at -70˚C for performing the BRS-3 protein assays.
Equal amounts of tissue lysates from each muscle sample 
were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (21), in parallel with molecular 
weight markers, on an 8% resolving gel. The separated proteins 
were then transferred onto a nitrocellulose membrane in a 
semi-dry system (Trans-Blot SD Semi-dry Transfer Cell; 
Bio-Rad, Hercules, CA, USA). For immunodetection, a western 
blotting kit was used following the manufacturer's instructions 
(Amersham Biosciencies), using total and phosphorylated (PKB, 
p70s6K and MAPKs) antibodies. In addition, p90RSK1 phos-
phorylated antibody, as well as BRS-3 antibody and α-tubulin 
antibody (internal loading control) were used. As the secondary 
antibody, horseradish peroxidase-conjugated donkey anti-rabbit 
immunoglobulin was used, and detection was carried out by 
enhanced chemiluminescence and quantification by autoradi-
ography and densitometry, as previously described (22).
The densitometric measurements of the phosphorylated 
protein kinase or BRS-3 protein were normalized (percentage 
phosphorylated/total kinase or α-tubulin) to the value obtained 
from the myocytes incubated in the absence of the peptide 
which was used as the control value.
Glucose transport. The myocytes were treated as previously 
described in the study by González et al (19). Briefly, the cells 
were pre-incubated for 30 min at 37˚C without (control) or 
with [D-Tyr6,β-Ala11,Phe13,Nle14]bombesin6-14 (10-12 to 10-7 M) 
or insulin (10-8 M), followed by 5 min of incubation at 37˚C 
in the additional presence of 0.2 µCi (6.5 pmol) 2-deoxy-D-
[1,2-3H(N)]glucose. The myocytes, after being washed for 
the removal of radioactivity incorporated into the cells, were 
scraped, dissolved in 1 ml 1 N NaOH and were then added 
to 3 ml scintillation liquid for β-counting. The total glucose 
content was corrected by the unspecific glucose uptake value, 
obtained in some of the cell samples from each experiment 
treated in parallel with 0.1 mM cytochalasin B.
Glycogen synthase a (GSa) activity. GSa activity was examined 
in cells incubated in DMEM, at 37˚C for 10 min, in the absence 
(control) or presence of BRS-3 agonist or insulin. The myocytes 
were immediately homogenized (FNa 100 mM, glycogen 
0.5% w/v, glycylglycine 50 mM, EDTA 35 mM, pH 7.4) and 
frozen at 160 µg protein/40 µl until the enzymatic activities were 
assayed. A total of 80 µl of [UDP-glucose 0.375 mM, glycogen 
1.5% w/v, glycylglycine 90 mM, Na2SO4 15 mM, UDP-14C-glucose 
0.375 µM (1.25 µC/ml), pH 7.4] and 40 µl of homogenized cells 
were incubated at 20˚C for 15 min. The reaction was terminated 
by the addition of 200 µl potassium hydroxide (KOH) (0.5 N) at 
4˚C. The final glycogen extraction was carried out as previously 
described in the study by Fleig et al (23).
Statistical analysis. The results are expressed as the 
means ± SEM, together with the number of observations (n). 
The statistical significance (p<0.05) of the increments was 
assessed by one-way analysis of variance (ANOVA), according 
to Levene's test, all variances were homogeneous, followed by 
the post-hoc Bonferroni test, using the Statistical Package for 
Social Sciences (SPSS 21.0).
Results
BRS-3 expression. In order to evaluate the potential role of 
the BRS-3 receptor in glucose homeostasis, we investigated 
the BRS-3 gene/protein expression levels in the skeletal 
muscle sections obtained from the patients with OB/T2D, and 
compared these levels to those of the normal patients.
As shown in Fig. 1A, In 5 patients with OB/T2D, the 
BRS-3 mRNA levels were significantly lower (23.6±1.3-fold 
downregulation, p<0.001) compared to the normal subjects 
(n=19). These results are in accordance with those obtained 
for BRS-3 protein expression (Fig. 1B); a significant decrease 
was observed in the protein expression levels of BRS-3 in the 
patients with OB/T2D (n=3), compared to 3 normal subjects.
Cell signaling. When cultured myocytes from patients with 
OB/T2D (n=5) were examined in parallel with those from 
the normal subjects (n=2), the basal phosphorylation levels of 
PKB, p70s6K, p42/p44 MAPKs and p90RSK1 were signifi-
cantly lower (p<0.001) in the cells from patients with OB/T2D 
compared to those from the normal subjects (Fig. 2).
In order to determine the signaling pathways involved in 
the activation of the BRS-3 receptor, we investigated the ability 
of the BRS-3 agonist to interact with this receptor, using a 
primary myocyte culture from 5 patients with OB/T2D. The 
results obtained for 4 kinases examined in the present study 
revealed that in the patients with OB/T2D, the increased 
phosphorylation of these enzymes was observed in response 
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to treatment with [D-Tyr6-β-Ala11,Phe13,Nle14]bombesin6-14. The 
presence of insulin also stimulated the activity of PKB, p70s6K, 
p42/p44 MAPKs and p90RSK1. Specifically, treatment with the 
BRS-3 agonist at 10-11 to 10-8 M slightly increased the PKB phos-
phorylation levels (overall mean, 126±2% of control; p<0.02)l; 
these levels were lower (p<0.0001) than those obtained by treat-
ment with 10-9 M insulin (Fig. 3). Distinctively, the activation 
of p70s6K induced by treatment with 10-10 M ligand (p=0.029), 
did not differ from that obtained by treatment with 10-9 M 
insulin (Fig. 3). When higher concentrations of [D-Tyr6-β-
Ala11,Phe13,Nle14]bombesin6-14 were used (10-9-10-8 M), no 
significant increments were detected (overall mean, 109±4% 
of control) compared to the basal values (Fig. 3). However, 
when cells from patients with OB/T2D were incubated in 
the presence of [D-Tyr6-β-Ala11,Phe13,Nle14]bombesin6-14, the 
expression pattern of the p42/p44 MAPKs differd (Fig. 3). The 
expression of both enzymes achieved the maximal increment 
following treatment with 10-11 of the compound; however, this 
expression decreased following treatment with higher concen-
trations of the ligand (10-10 and 10-9 M), although the expression 
was maintained at a higher level compared to the basal level 
(Fig. 3). Moreover, the stimulatory effects induced by insulin at 
10-9 M on p44 MAPK phosphorylation were significantly less 
prominent compared to the effects induced by treatment with 
10-11 M agonist (Fig. 3). As regards the p90RSK1 phosphoryla-
tion levels (Fig. 3), a relevant increase was observed following 
treatment with 10-11 M of the BRS-3 ligand (148±2% of the 
control, p<0.0001); the p90RSK1 phosphorylation levels were 
at similar levels following treatment with 10-10 to 10-8 M of the 
agonist and 10-9 M insulin (Fig. 3).
Glucose transport and GSa activity. Glucose transport and 
GSa activity are essential parameters of glucose homeostasis in 
muscle tissue. Due to their relevance, we examined the effects 
of the BRS-3 agonist on glucose transport and metabolism 
in cultured primary human myocytes from 4 patients with 
OB/T2D (Table II).
The presence of the BRS-3 ligand elicited a stimula-
tion of glucose transport [with respect to the value obtained 
in the cells incubated in the absence of the peptide 
(15.7±2.4 fmol/2x104 cells, n=4)], which was almost signifi-
cant (p=0.082) following treatment with the ligand at 10-12 M 
(20.8±1.4 fmol/2x104 cells, n=4), reached a maximal level at 
10-11 M (25.1±1.4 fmol/2x104 cells, n=4, p<0.001), and was there-
after maintained up to the dose of 10-8 M (overall mean value: 
23.7±1.1 fmol/2x104 cells, n=4, p<0.008), and then slightly 
Figure 2. PKB, p70s6K, p42/p44 MAPKs and p90RSK1 phosphorylated 
forms, in cultured primary myocytes from patients with obesity and and type 2 
diabetes (OB/T2D) compared to normal subjects (N). Results (means ± SEM) 
are expressed relative to the control value obtained from cells from normal 
subjects. Patients with OB/T2D, n=5 and normal sujbects, n=2; (A) representa-
tive immunoblots, and (B) quantitative analysis. *p<0.001 OB/T2D vs. normal 
sujbects.
Figure 1. Bombesin receptor subtype-3 (BRS-3) gene expression and pro-
tein levels in muscle tissue sections from patients with obesity and type 2 
diabetes (OB/T2D) and normal subjects. (A) BRS-3 gene expression level in 
skeletal muscle tissue sections. Values (means ± SEM) are expressed as copy 
of numbers by using the Ct value relative to that of the normal subjects after 
normalization against 18S rRNA (2-ΔΔCt). Patients with OB/T2D, n=5 and 
normal subjects, n=19. *p<0.001, OB/T2D vs. normal subjects. (B) BRS-3 pro-
tein expression level in skeletal muscle tissue sections. Values (means ± SEM), 
corresponding to total protein extracted are expressed as a percentage of 
measurements relative to the normal subjects. Patients with OB/T2D, n=5 and 
normal subjects,n=4; upper panel corresponds to a representative immunoblot, 
and lower panel represents quantitative analysis of the BRS-3 protein level. 
*p<0.001 OB/T2D vs. normal subjects.
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decreased by treatment at 10-7 M (20.4±1.1 fmol/2x104 cells, 
n=4). Despite the fact that the maximal stimulatory effect of the 
BRS-3 agonist on glucose transport was produced by treatment 
with 10-11 M of the compound, treatment with 10-9 M insulin 
(Table II), achieved a significantly higher net glucose uptake 
(31.8±1.4 fmol/2x104 cells, n=4, p=0.009 vs. treatment with 
10-11 M BRS-3 agonist).
The ligand clearly increased GSa activity in the myocytes 
obtained from 4 patients with OB/T2D (Table II). Specifically, 
treatment with 10-11 M of the compound induced the maximal 
increase in enzyme activity (0.020±0.001 U/g protein, n=4, 
p<0.0001), compared to the value obtained in the cells incu-
bated in the absence of peptide (0.020±0.0013 U/g protein, 
n=4). This effect was equal to that exerted by insulin (10-9 M, 
0.029±0.002 U/g protein, n=4, p<0.0001 vs. control) (Table II). 
Although treatment with higher concentrations of the ligand 
(10-10 M, 0.031±0.002 U/g protein, n=4, p<0.0001 vs. control; 
10-9 M, 0.028±0.002 U/g protein, n=4, p=0.0008 vs. control; 
10-8 M, 0.028±0.002 U/g protein, n=4, p<0.0001 vs. control) 
produced significant increases in GSa activity, it did not 
improve the cellular response to the BRS-3 agonist (Table II).
Discussion
Studies on the BRS-3 receptor in muscle cells from patients with 
OB/T2D have demonstrated its role in glucose homeostasis (13). 
In this regard, the BRS-3 receptor is considered a molecular 
target; therefore, a BRS-3 agonist with insulin-mimetic effects 
may be used as a therapeutic tool for these patients (5,18).
In this study, we focused on patients simultaneously diag-
nosed with OB/T2D, in order to determine BRS-3 expression 
levels in skeletal muscle sections and to assess the effects of the 
BRS-3 agonist, [D-Tyr6-β-Ala11,Phe13,Nle14]bombesin6-14, on 
glucose-related processes in primary cultured myocytes.
In the analysis of the 10 patients with OB/T2D included in 
this study, the range of variability in the clinical parameters was 
kept as minimal as possible between the normal subjects and 
the patients. The standard treatment for T2D is metformin, and 
cells from the 2 study groups showed an equal growth rate and 
morphology, as previously observed in myocytes from patients 
with OB/T2D compared to cells from normal subjects (18). 
Sample collection and classification was extremely chal-
lenging, due to the requirements in terms of consistency and 
homogeneity of the samples obtained from patients with OB/
T2D. However, the recruitment of normal subjects based on 
metabolic characteristics was less complex due to the higher 
availability of such individuals.
The analysis of BRS-3 gene expression in muscle sections 
obtained from patients with OB/T2D exhibited a marked 
Figure 3. Effect of treatment with 10-11 to 10-8 M [D-Tyr6-β-Ala11,Phe13,Nle14]
bombesin6-14 and insulin on PKB, p70s6K, p42/p44 MAPK and p90RSK1 phos-
phorylation in cultured primary human myocytes from patients with obesity 
and type 2 diabetes (OB/T2D) incubated for 3 min. (A) Representative immu-
noblots. (B) Quantitative analysis of enzyme phosphorylation levels; values 
(means ± SEM) are relative to the respective paired control obtained form cel-
lular samples incubated in the absence of the peptide corresponding to patients 
with OB/T2D (n=5). *p<0.02 vs. control; †p<0.0001 vs. treatment with insulin.
Table II. Effect of [D-Try6,β-Ala11,Phe13,Nle14]bombesin6-14 and insulin on glucose transport and glycogen synthase a activity in 
myocytes from patients with obese/type 2 diabetes (OB/T2D). 
 % of paired control
 [D-Try6,β-Ala11,Phe13,Nle14]bombesin6-14 Insulina -------------------------------------------------------------------------------------------------------------------------------------- ---------------
 Control       10-8 M/
 no peptide 10-12 M 10-11 M 10-10 M 10-9 M 10-8 M 10-7 M 10-9 M
Glucose transport 15.7±2.4 fmol/ 133±9 160±9a 146±12a 147±9a 167±14a 130±8 202±9a,b
 2x104 cells
Glycogen synthase a 0.020±0.001 U/g - 165±16a 153±11a 140±10a 142±11a - 147±9a
Results are the means ± SEM; n=4 ap≤0.008 vs. control; bp=0.009 vs. treatment with 10-11 M [D-Try6,β-Ala11,Phe13,Nle14]bombesin6-14. aThe 
maximal effect on glucose transport was induced by 10-8 insulin; in signaling and metabolic assays (i.e., glycogen synthase a activity), the maximal 
effect induced by insulin was achieved at 10-9.
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decrease in BRS-3 compared to the normal subjects. This 
finding is in agreement with the results from a previous study, 
where a decrease in the mRNA expression levels of BRS-3 in 
the muscle tissue of patients with metabolic conditions was 
detected (5). However, the expression level of BRS-3 in patients 
with OB/T2D reported in this study was much lower than 
that previously observed in patients affected by either T2D or 
obesity (5), thus suggesting a potential synergy in the negative 
impact of these 2 conditions on BRS-3 gene expression.
The analysis of BRS-3 protein levels showed some similar-
ities and differences with previous data. Our results revealed 
that the BRS-3 protein expression levels in muscle tissue were 
significantly lower in patients with OB/T2D compared to 
the normal subjects. This reduction was not different to that 
observed in T2D patients (5); however, it was lower than the 
level reported in obese patients (5).
These facts underline the importance of a functional BRS-3 
receptor in altered metabolic states in humans. Its significance 
has already been suggested by Ohki-Hamazaki et al (2), whose 
study indicated that mice lacking functional BRS-3 developed 
mild obesity, associated with hypertension and an impairment 
of glucose metabolism, a reduced metabolic rate, increased 
feeding efficiency and subsequent hyperphagia.
In vitro experiments carried out on myocytes from normal 
subjects and patients with obesity or T2D have demonstrated 
the ability of insulin to enhance BRS-3 expression (5), which 
may also be a possible mediator in the regulation of BRS-3 
gene expression, as BRS-3 expression has been detected in 
cells expressing high levels of insulin receptor, such as fibro-
blasts, where certain regulatory processes are produced by the 
hormone (24,25). In muscle biopsies from patients with T2D 
(daily treatment with insulin prior to surgery), the decrease in 
the mRNA expression level of BRS-3 compared to the levels 
of the normal subjects was similar to the decrease detected in 
the muscle tissue sections from patients with obesity (5). It was 
also obseved that patients with OB/T2D receiving anti-diabetic 
drugs orally showed a maximal decrese in BRS-3 gene expres-
sion. Therefore, further studies are required to fully elucidate 
the effects of insulin and oral anti-diabetic drugs on BRS-3 
expression in muscle biopsies from patients with OB/T2D.
Recently, the use of several BRS-3 agonists has been 
demonstrated to define BRS-3-signaling pathways. MK-5046 
and a modified synthetic bombesin compound [D-Tyr6,β-
Ala11,Phe13,Nle14]bombesin6-14 (17) have been shown (in a 
mouse fibroblast cell line transfected with human BRS-3) to 
increase p125FAK, pAKT and MAPK phosphorylation (17). 
Moreover, in primary myocytes isolated from normal 
subjects and patients with altered metabolic states (patients 
with obesity or T2D, where BRS-3 is natively expressed), 
the insulin-mimetic effects of [D-Tyr6,β-Ala11,Phe13,Nle14]
bombesin6-14 have been observed (18). Increases in MAPK, 
p90RSK1, PKB and p70s6K phosphorylation were detected, 
with myocytes from patients with obesity and T2D being 
more sensitive to the ligand than those from normal subjects; 
cells from patients with T2D were even more sensitive than 
those from patients with obesity (18). Our results obtained 
from myocytes from patients with OB/T2D, showed a higher 
sensitivity of these cells to the agonist compared to cells from 
normal subjects. The BRS-3 agonist at 10-11 M induced the 
maximal p42/p44 MAPK and p90RSK1 phosphorylation, 
which was higher than that previously detected in cells from 
patients with T2D (18). However, in myocytes from patients 
with OB/T2D, although the presence of the ligand at the 
same concentration exerted a significant stimulatory effect on 
PKB and p70s6K phosphorylation, this effect did not differ 
to that previously observed in myocytes from patients with 
T2D (18). The basal phosphorylation levels of PKB, p70s6K, 
p42/p44 MAPKs and p90RSK1 were significantly lower 
in the cells from patients with OB/T2D compared to those 
from normal subjects, as previously observed in patients with 
obesity, apart from p90RSK-1, where no modification was 
reported (18,26). However, in cells from patients with T2D, no 
decrease in basal kinase activity was detected (18,27), which 
seems to reflect a major influence of obesity on the reduced 
basal level detected in patients with OB/T2D. Although it is 
not conclusive, this finding is in agreement with the findings 
from studies on adipocytes from rats with T2D, demonstrating 
that the basal phosphorylation levels of these kinases did not 
differ significantly from those detected in animals without 
metabolic alterations (28). This finding has also been shown in 
adipocytes from patients with obesity, with the respective basal 
activity of PKB, MAPKs, but not p70s6K, being decreased 
compared to that of the corresponding normal subjects (29). By 
contrast, it has been found that in soleus muscle samples from 
rats with T2D, PKB phosphorylation levels were lower than 
those observed in normal rats, whereas the phosphorylation 
levels of MAPKs and p70s6K were significantly higher (30).
Further assays were performed in cells from patients with 
OB/T2D in order to investigate 2 key parameters of glucose 
homeostasis, glucose transport and GSa activity. The results 
revealed that either variable, the glucose uptake or enzyme 
activity, was increased in the presence of the BRS-3 agonist. 
Specifically, treatment of the cells from patients with OB/T2D 
with 10-12 M of the compound induced a significant incre-
ment in glucose transport, with maximal effects observed at 
10-11 M. This finding suggests a relevant sensitivity of cells 
from patients with OB/T2D to the BRS-3 ligand. Although no 
effects of insulin on glucose uptake in adipocytes in BRS-3-KO 
mice (possibly due to an impaired GLUT-4 translocation) has 
been observed (11), in our study, in myocytes from patients 
with OB/T2D, both the BRS-3 agonist and insulin affected 
glucose transport, as has been previously reported in myocytes 
from patients with either OB or T2D (5,26,27).
Our results revealed that in myocytes from patients 
with OB/T2D, treatment with [D-Tyr6,β-Ala11,Phe13,Nle14]
bombesin6-14 at 10-11 M induced a significant increase in 
GSa activity similar to that exerted by higher concentrations 
of insulin (10-9 M), almost having a normalizing effect, as 
previousy observed in patients with in OB or T2D (18). The 
activation of GSa is preceded by the inhibition of glycogen 
synthase kinase-3 (GSK-3), which is closely related to p70s6K, 
p42/44 MAPKs and p90RSK1 (18,31,32). Previous studies, as 
well as the current study found an increase in the p90RSK1 
phosphorylation levels induced by [D-Tyr6,β-Ala11,Phe13,Nle14]
bombesin6-14 through the BRS-3 receptor (18), which seems to 
be related to the transcription factor, CREB (33), involved in 
BRS-3 activation in humans (18,34).
In conclusion, currently available information on the BRS-3 
receptor (gene regulation, activation, binding or signaling 
pathways) is limited. However, recent studies (5,18), as well 
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as the data from the present study, emphasize the importance 
of this receptor in human metabolic conditions. The novelty 
of the present study lies in the fact that it was conducted on 
skeletal muscle samples from patients being simultaneously 
affected by 2 major metabolic disoders, i.e. obesity and 
T2D. Our results further support the concept that the BRS-3 
receptor and its synthetic agonist may prove to be useful as a 
therapeutic target in the treatment of patients with OB/T2D.
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